Limiting dilution assays are widely used in infectious disease research. These assays are
crucial for current human immunodeficiency virus (HIV)-1 cure research in particular. In this …

Antiretroviral therapy fails to cure HIV-1 infection because latent proviruses persist in resting
CD4 + T cells. T cell activation reverses latency, but <1% of proviruses are induced to …

The odds of living a long and healthy life with HIV infection have dramatically improved with
the advent of combination antiretroviral therapy. Along with the early development and …

The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1)
eradication strategies 1 , 2 , 3 , 4 , 5 . However, it remains unclear when and where …

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better
understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from …

The problem of achieving widespread immunity to infectious diseases by voluntary vaccination
is often presented as a public-goods dilemma, as an individual's vaccination contributes …

Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will
likely require effective drug combinations to achieve high levels of latency reversal. Using …

A latent reservoir for HIV-1 in resting CD4 + T lymphocytes precludes cure. Mechanisms
underlying reservoir stability are unclear. Recent studies suggest an unexpected degree of …

Massive research efforts are now underway to develop a cure for HIV infection, allowing
patients to discontinue lifelong combination antiretroviral therapy (ART). New latency-reversing …

Precision medicine in cancer proposes that genomic characterization of tumors can inform
personalized targeted therapies 1 , 2 , 3 , 4 , 5 . However, this proposition is complicated by …